Trial Profile
ALL09 - Phase II Study of Blinatumomab as Induction Therapy in Adolescent and Young Adult Acute Lymphoblastic Leukaemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms The SUBLIME Study
- 12 Dec 2023 Results from this and other study assessing impact of blin on outcomes in genomic cohorts, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Primary endpoint (To assess the rate of minimal residual disease (MRD) negativity, where MRD negativity is defined as no presence of leukaemic blasts in blood or bone marrow sample as determined by EuroMRD accredited q-pcr analysis) has been met according to results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results assessing whether the substitution of standard multi-agent cytotoxics with blinatumomab in protocol I phase 2 (consolidation) of a BFM based protocol in de novo AYA CD19+ ALL would be associated with improved day 79 MRD negativity rates and subsequent improvements in DFS and OS when compared to the ALL06 trial presented at the 64th American Society of Hematology Annual Meeting and Exposition